3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
5
Neoplasms
3
Uveal Melanoma
2
Prostatic Neoplasms
2
Stomach Neoplasms
1
Renal Insufficiency, Chronic
1
Oligodendroglioma
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Glioma
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bile Duct Neoplasms
1
Astrocytoma
1
Interventions
Nivolumab
74
Sunitinib
73
pembrolizumab
49
Everolimus
39
Sorafenib
36
Bevacizumab
36
Axitinib
36
cabozantinib
35
Radiosurgery
33
Ipilimumab
33
pazopanib
32
Magnetic Resonance Spectroscopy
27
Interleukin-2
27
aldesleukin
23
Specimen Handling
22
Cyclophosphamide
21
lenvatinib
20
fludarabine phosphate
17
Radiotherapy
16
Interferon-alpha
15
Peripheral Blood Stem Cell Transplantation
14
Gemcitabine
14
Biopsy
14
temsirolimus
13
Nephrectomy
13
durvalumab
11
Immunohistochemistry
11
CTLA-4 Antigen
11
Blood Specimen Collection
11
Capecitabine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Renal Cell
×
Protein Subunit Vaccines
×
Clear all
NCT02429440
2017-08-17
UroRCC
University Hospital Tuebingen
Phase 1/2
Unknown
40 enrolled